[1]
V. B., “A REVIEW ON THE DEVELOPMENT OF FAVIPRAVIR AGAINST SARS COV 2 INFECTION”, Int J Curr Pharm Sci, vol. 14, no. 2, pp. 11–14, Mar. 2022.